Healthy persons versus pacients with diabetes mellitus type 2 – choosen parameters in serum and subcutaneous abdominal adipose tissue

Czech version

Authors: R. Ben Yahia ¹; R. Lichnovská ¹; L. Janušová ¹; G. Kuzmina ¹; M. Karpíšek ^2,3; D. P. Kollár ³; J. Petřek ¹
Authors‘ workplace: Ústav fyziologie Lékařské fakulty UP Olomouc, přednosta prof. MUDr. Josef Petřek, CSc. ¹; BioVendor Laboratoře Brno ²; Ústav farmakologie a toxikologie Farmaceutické fakulty Veterinární univerzity Brno, přednosta doc. MUDr. Jiří Nečas, CSc. ³
Published in: Vnitř Lék 2007; 53(1): 9-17
Category: Original Contributions

Overview

Endocrinal products of adipocytes (PPARγ, A-FABP, E-FABP, leptin, adiponectin and others) modulate insulin tissue sensitivity enabling them to participate in the ethiopathogenesis of diabetes mellitus type 2 (DM2T). Persons with DM2T are characterised by typical changes in lipid spectrum (lower HDL-cholesterol and higher TAG) and in the endocrinal function of subcutaneous adipose tissue; adipocytes produce more PPARγ, A-FABP and E-FABP and less adiponectin.

Aims of the study:
To measure chosen markers of metabolic syndrome (MS) in serum and in abdominal subcutaneous adipose tissue in healthy persons and patients with DMT2, to determine basic statistical characteristics of investigated parameters and to discus their role in the genesis and progress of the MS.

Methods:
Samples of blood and abdominal subcutaneous adipose tissue were collected from each participant (healthy: 7 men and 8 women; diabetics: 18 men, 11 women) to investigate the levels of HDL, TAG, insulin, C-peptide, glycaemia and the concentrations of A-FABP, E-FABP, leptin, adiponectin, resistin, PPARγ and TNFα. Results: In most cases the average concentration of investigated parameters in serum was higher in persons with DM 2 regardless of gender. Lower values were only found for HDL and adiponectin. The same situation prevailed in the subcutaneous adipose tissue. Values of most other parameters (A-FABP, E-FABP, and PPARγ) were also higher in patients. The values of measured parameters not only differed in healthy and in sick persons but depended on gender. The increase/decrease in concrete parameters was greater in diabetic women than diabetic men.

Conclusion:
Higher concentrations of A-FABP, E-FABP in serum and in subcutaneous adipose tissue in diabetic persons also higher concentrations of PPARγ in subcutaneous adipose tissue suggest that these investigated parameters are closely associated with obesity and MS. We can assume that in the near future these parameters will be used in clinical work for diagnosis of this syndrome.

Key words:
A-FABP - E-FABP - Adiponectin - PPARγ - Subcutaneous adipose tissue - diabetes mellitus type 2

Sources

1. Svačina Š, Owen K. Obezita, diabetes 2. typu a jejich kvantitativní vztahy. Vnitř Lék 2002; 48: 500-506.

2. Krempler F, Breban D, Oberkofler H et al. Leptin, peroxisome proliferator-activated receptor-γ, and CCAAT/enhancer binding protein-α mRNA expression in adipose tissue of humans and their relation to cardiovascular risk factors. Arterioscler Thromb Vasc Biol 2000; 20: 443-449.

3. Sivitz WI, Wayson SM, Bayless ML et al. Leptin and body fat in type 2 diabetes and monodrug therapy. J Clin Endocrinol Metab 2003; 88: 1543-1553.

4. Zamboni M, Zoico E, Fantin F et al. Relation between leptin and the metabolic syndrome in elderly women. J Gerontol A Biol Sci Med Sci 2004; 59: 396-400.

5. Miyazaki Y, Mahankali A, Wajcberg E et al. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2004; 89: 4312-4319.

6. Fischer RM, Thorne A, Hamsten A et al. Fatty acid binding expression in different human adipose tissue depots in relation to rates of lipolysis and insulin concentration in obese individuals, Mol Cell Biochem 2002; 239: 95-100.

7. Boord JB, Maeda K, Makowski L et al. Combined adipocyte-macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice. Circulation 2004; 110: 1492-1498.

8. Memon RA, Tecott LH, Nonogaki K et al. Up-regulation of peroxisome proliferator-activated receptors (PPAR-α) and PPAR-γ messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-γ-responsive adipose tissue-specific genes in the liver of obese diabetic mice. Endocrinology 2000; 141: 4021-4031.

9. Hřebíček J. PPAR: Úloha v homeostáze glukózy a lipidů, v inzulinové rezistenci a v ateroskleróze (in Czech). Cs Fyziol 2004; 53: 4-14.

10. Peters JM, Lee SS, Li W et al. Growth adipose brain and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β/δ. Mol Cell Biol 2000; 20: 5119-5128.

11. Spiegelman B.M PPARγ in monocytes: less pain, any gain? Cell 1998; 93: 153-155.

12. Kawaguchi K, Sugiyama T, Hibasami H et al. PPAR-γ, TNF-α messenger RNA levels and lipase activity in the pregnant and lactating rat. Life Sci 2003; 72: 1655-1663.

13. Auboeuf D, Rieusset J, Fajas L. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-αin adipose tissue of obese and NIDDM patients. Diabetes 1997; 46: 1319-1327.

14. Mukherjee R, Jow L, Croston GE et al. Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoform PPARγ2 versus PPARγ1 and activation with retinoid X receptor agonists and antagonists. J Biol Cel 1997; 272: 8071-8076.

15. Vidal-Puig AJ, Considine RV, Jimenez-Linan M et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity weight loss and regulation by insulin and glucocorticoids. J. Clin Invest 1997; 99: 2416-2422.

16. Zierath JR, Frevert EU, Ryder JW et al. Evidence against a direct effect of leptin on glukose transport in skeletal Musile and adipocytes. Diabetes 1998; 47: 1-4.

17. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 1994; 30: 1147-1156.

18. Heitzel AV, Bemlohr DA. Regulation of adipocyte gene expression by polyunsaturated fatty acids. Mol Cell Biochem 1998; 188: 33-39.

19. Schoonjans K, Staels B, Grimaldi P et al. Acyl-CoA synthetase mRNA expression is controlled by fibric-acid derivates feeding and liver proliferation. Eur J Biochem 1993; 216: 615-622.

20. Martin G, Schoonjans K, Lefebvre AM et al. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA syntethase genes by PPARα and PPARγ activators. Biol Chem 1997; 272: 28210-28217.

21. Auwerx J, Schoonjans K, Fruchart JC et al. Transcriptional control of triglyceride metabolism; fibrates change the expression of LPL and apo C-111 genes by activating the nuclear receptor PPAR. Atherosclerosis 1996; 124: S29-S37.

22. Boyle PJ. What are the effects of peroxisome proliferators-activated receptor agonists on adiponectin, tumor necrosis factor-α, and other cytokines in insulin resistance? Clin Cardiol 2004; 27(Suppl 4): IV11-IV16.

23. Haluzík M, Gavrilova O, LeRoith D. Peroxisome proliferator-activated receptor-α deficiency does not alter insulin sensitivity in mice maintained on regular or high-fat diet: hyperinsulinemic-euglycemic clamp studies. Endokrinology 2004; 145: 1662-1667.

24. Matsuzava Y, Shimomura I, Kihara S et al. Importance of adipocytokines in obesity-related diseases. Hormon Res 2003; 60(Suppl 3): 56-59.

25. Shimada T, Kojima K, Yoshiura K et al. Characteristics of the peroxisome proliferators activated receptors gamma (PPARγ) ligand induced apoptosis in colon cancer cells. Gut 2002; 50: 658-664.

26. Coppola G, Corrado E, Muratori I et al. Increased levels of C-reactive protein and fibrinogen influence the risk of vascular events in patients with NIDDM. Int J Cardiol 2006; 106: 16-20.

27. Xu A, Wang Y, Xu JY et al. A dipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 2006; 52: 405-413.

28. Gultekin T, Akin G, Ozer BK. Gender differences in fat patterning in children living in Ankara. Anthropol Anz 2005; 63: 427-437.

29. Machann J, Thamer C, Schnoedt B et al. Standardized assessment of whole body adipose tissue topography by MRI. J Magn Reson Imaging 2005; 21: 455-462.

30. Bonora E, Del Prato S, Bonadonna RC et al. Total body fat content and fat topography are associated differently with in vivo glucose metabolism in nonobese and obese nondiabetic women. Diabetes 1992; 41: 1151-1599.

31. Pietilainen KH, Kannisto K, Korsheninnikova E et al. Acquired obesity increases CD68 and TNF-α and decreases adiponectin gene expression in adipose tissue. A study in monozygotic twins. J Clin Endocrinol Metab 2006; přijato do tisku.

32. Koshiba K, Nomura M, Nakaya Y et al. Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis Med Invest 2006; 53: 87-94.

33. Smith JD, Al-Amri M, Sniderman AD et al. Leptin and adiponectin in relation to bo dy fat percentage, waist to hip ratio and the apoB/apoA1 ratio in Asian Indian and Caucasian men and women. Nutr Metab (London) 2006; přijato do tisku.

34. Lacquemant C, Vasseur F, Lepretre F et al. Adipocytokins, obesity and development of type 2 diabetes (in French). Med Sci (Paris) 2005; Spec No 10-18.

35. Kim SH, Abbasi F, Chu JW et al. Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin clearance in nondiabetic, insulin-resistant individuals. Diabetes 2005; 54: 2447-2452.

36. Carmina E, Orio F, Palomba S et al. Endothelial dysfunction in PCOS: role of obesity and adipose hormones. Am J Med 2006; 119: 356.

37. Hojlund K, Frystyk J, Levin K et al. Reduced plasma adiponectin concentration may contribute to impaired insulin activation of glycogen synthase in skeletal muscle of patients with type 2 diabetes. Diabetologia 2006; přijato do tisku.

38. Sun X, Han R, Wang Z et al. Regulation of adiponectin receptors in hepatocytes by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone. Diabetologia 2006; přijato do tisku.